Affordability and Price Increases of New Cancer Drugs in Clinical Guidelines, 2007–2016. Issue 2 (1st June 2018)

• Record Type: Journal Article
• Authors: Hwang, Thomas J; Kesselheim, Aaron S; Gyawali, Bishal
• Is Part Of: JNCI cancer spectrum. Volume 2:Issue 2(2018)
• Publication Date: 2018-06-01
• DOI: 10.1093/jncics/pky016
• Languages: English
• ISSNs: 2515-5091

Abstract

Abstract: In response to the rising cost of cancer drugs, the National Comprehensive Cancer Network (NCCN) recently developed a value framework, known as "Evidence Blocks, " to grade the efficacy, safety, evidence quality, evidence consistency, and affordability of treatments included in its clinical guidelines. The value scores were available for 55 of the 69 new cancer drugs approved by the US Food and Drug Administration from 2007 to 2016. Overall, the treatment costs for 95% of new cancer medicines in NCCN clinical guidelines were scored as "very expensive" or "expensive". In multivariable ordered logistic regression models, there was no association between the affordability of new cancer drugs and efficacy and safety data available in clinical guidelines. Most guideline-recommended drugs were subject to annual list price increases exceeding inflation.